32 results on '"Costa, Daniel B."'
Search Results
2. Scientific Advances in Thoracic Oncology 2016
3. Lung Adenocarcinoma Manifesting as Pure Ground-Glass Nodules: Correlating CT Size, Volume, Density, and Roundness with Histopathologic Invasion and Size
4. Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy
5. Pulse Afatinib for ERBB2 Exon 20 Insertion–Mutated Lung Adenocarcinomas
6. Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations
7. Adequacy of Lymph Node Transbronchial Needle Aspirates Using Convex Probe Endobronchial Ultrasound for Multiple Tumor Genotyping Techniques in Non–Small-Cell Lung Cancer
8. Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung
9. Esophagitis: A Novel Adverse Event of Crizotinib in a Patient with ALK-Positive Non–Small-Cell Lung Cancer
10. Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
11. EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer
12. Preclinical Rationale for Use of the Clinically Available Multitargeted Tyrosine Kinase Inhibitor Crizotinib in ROS1-Translocated Lung Cancer
13. Acquired Resistance to the ALK Inhibitor Crizotinib in the Absence of an ALK Mutation
14. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples
15. ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers
16. KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma
17. Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1–Positive Lung Cancer
18. Serum Concentrations of Erlotinib at a Dose of 25 mg Daily
19. Erlotinib-Associated Alopecia in a Lung Cancer Patient
20. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer
21. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma
22. Authors’ Response
23. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non–Small Cell Lung Cancer
24. Updated Correlation of 22C3-PD-L1 ≥50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor–Resistant Setting
25. Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies
26. Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma
27. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFRC797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFRT790M/C797S in Preclinical Models and Clinical Samples
28. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma
29. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALKI1171S in ALK-Rearranged Lung Cancer
30. Pulse Afatinib for ERBB2Exon 20 Insertion–Mutated Lung Adenocarcinomas
31. Compound Uncommon EGFRMutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies
32. Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced METExon 14 Skipping Mutation–Positive Lung Adenocarcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.